Inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1)

Journal of Steroid Biochemistry and Molecular Biology

Volumn 125, Issue 1-2, 2011, Pages 105-111

  El Kabbani, Ossama ^a   Dhagat, Urmi ^a   Hara, Akira ^b  

^a MONASH UNIVERSITY   (Australia)

^b GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

20 Hydroxysteroid dehydrogenase; 3 Hydroxysteroid dehydrogenase; Aldo keto reductase; Cancer; Drug design

Indexed keywords

2 (2',3 DICHLORO N METHYLBIPHENYL 4 YL CARBOXAMIDO)BENZOIC ACID; 2 (4 CHLOROBENZYLIDENE) CYCLOPENTANONE; 20ALPHA HYDROXYSTEROID DEHYDROGENASE; 3 BROMO 5 PHENYLSALICYLIC ACID; 3,7 DIHYDROXYFLAVONE; 3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 7 HYDROXYFLAVONE; ANTHRANILIC ACID DERIVATIVE; CYCLOPENTANE DERIVATIVE; EFENAMIC ACID; FLAVONE DERIVATIVE; LITHOCHOLIC ACID; MEDAZEPAM; N BENZYL 2 (2 (4 METHOXYBENZYL) 6 OXO 1,6 DIHYDROPYRIMIDIN 4 YL)ACETAMIDE; NARINGENIN; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; XENYSALATE;

ARTICLE; BINDING AFFINITY; CANCER CELL; COLON CARCINOMA; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; PROGNOSIS;

20-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MOLECULAR STRUCTURE;

EID: 79957723874     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.10.006     Document Type: Article

References (54)

1. R.P. Piekorz, S. Gingras, A. Hoffmeyer, J.N. Ihle, and Y. Weinstein Regulation of progesterone levels during pregnancy and parturition by signal transducer and activator of transcription 5 and 20α-hydroxysteroid dehydrogenase Mol. Endocrinol. 19 2 2005 431 440 (Pubitemid 40223467)
2. B. Gellersen, M.S. Fernandes, and J.J. Brosens Non-genomic progesterone actions in female reproduction Hum. Reprod. Update 15 1 2009 119 138
3. D.G. Stein Progesterone exerts neuroprotective effects after brain injury Brain Res. Rev. 57 2 2008 386 397 (Pubitemid 351381771)
4. G. Xiao, J. Wei, W. Yan, W. Wang, and Z. Lu Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial Crit. Care 12 2 2008 R61
5. I. Roglio, R. Bianchi, S. Gotti, S. Scurati, S. Giatti, M. Pesaresi, D. Caruso, G.C. Panzica, and R.C. Melcangi Neuroprotective effects of dihydroprogesterone and progesterone in an experimental model of nerve crush injury Neuroscience 155 3 2008 673 685
6. E. Leonelli, R. Bianchi, G. Cavaletti, D. Caruso, D. Crippa, L.M. Garcia-Segura, G. Lauria, V. Magnaghi, I. Roglio, and R.C. Melcangi Progesterone and its derivatives are neuroprotective agents in experimental diabetic neuropathy: a multimodal analysis Neuroscience 144 4 2007 1293 1304 (Pubitemid 46123820)
7. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 351 Pt 1 2000 67 77
8. M. Quinkler, C. Bumke-Vogt, B. Meyer, V. Bähr, W. Oelkers, and S. Diederich The human kidney is a progesterone-metabolizing and androgen-producing organ J. Clin. Endocrinol. Metab. 88 6 2003 2803 2809 (Pubitemid 36724459)
9. Y. Zhang, M. Nadeau, F. Faucher, O. Lescelleur, S. Biron, M. Daris, C. Rhéaume, V. Luu-The, and A. Tchernof Progesterone metabolism in adipose cells Mol. Cell. Endocrinol. 298 1-2 2009 76 83
10. Y.E. Marín, M. Seiberg, and C.B. Lin Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival Exp. Dermatol. 18 7 2009 611 618
11. M. Quinkler, K. Kaur, M. Hewison, P.M. Stewart, and M.S. Cooper Progesterone is extensively metabolized in osteoblasts: implications for progesterone action on bone Horm. Metab. Res. 40 10 2008 679 684
12. P.E. Malone, and M.R. Hernandez 4-Hydroxynonenal, a product of oxidative stress, leads to an antioxidant response in optic nerve head astrocytes Exp. Eye Res. 84 3 2007 444 454 (Pubitemid 46210058)
13. Y. Higaki, N. Usami, S. Shintani, S. Ishikura, O. El-Kabbani, and A. Hara Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone Chem. Biol. Interact. 143-144 2003 503 513 (Pubitemid 36253599)
14. D.R. Bauman, S. Steckelbroeck, and T.M. Penning The roles of aldo-keto reductases in steroid hormone action Drug News Perspect. 17 9 2004 563 578 (Pubitemid 40136607)
15. O.A. Barski, S.M. Tipparaju, and A. Bhatnagar The aldo-keto reductase superfamily and its role in drug metabolism and detoxification Drug Metab. Rev. 40 4 2008 553 624
16. Y. Jin, and T.M. Penning Aldo-keto reductases and bioactivation/ detoxication Annu. Rev. Pharmacol. Toxicol. 47 2007 263 292
17. 2 11-ketoreductase activity J. Biochem. 124 5 1998 940 946 (Pubitemid 28544904)
18. 2 followed by micellar electrokinetic chromatography J. Sep. Sci. 31 4 2008 735 740 (Pubitemid 351419580)
19. M.E. Burczynski, G.R. Sridhar, N.T. Palackal, and T.M. Penning The reactive oxygen species- and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the α,β-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene J. Biol. Chem. 276 4 2001 2890 2897
20. S.H. Lee, and I.A. Blair Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation Chem. Res. Toxicol. 13 8 2000 698 702 (Pubitemid 30663446)
21. J.A. Doorn, S.K. Srivastava, and D.R. Petersen Aldose reductase catalyzes reduction of the lipid peroxidation product 4-oxonon-2-enal Chem. Res. Toxicol. 16 11 2003 1418 1423 (Pubitemid 37474091)
22. N.Y. Hsu, H.C. Ho, K.C. Chow, T.Y. Lin, C.S. Shih, L.S. Wang, and C.M. Tsai Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer Cancer Res. 61 6 2001 2727 2731
23. C.Y. Chen, C.P. Hsu, N.Y. Hsu, C.S. Shih, T.Y. Lin, and K.C. Chow Expression of dihydrodiol dehydrogenase in the resected stage I non-small cell lung cancer Oncol. Rep. 9 3 2002 515 519
24. T.L. Rizner, T. Smuc, R. Rupreht, J. Sinkovec, and T.M. Penning AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer Mol. Cell. Endocrinol. 248 1-2 2006 126 135
25. T. Smuc, and T.L. Rizner Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer Mol. Cell. Endocrinol. 301 1-2 2009 74 82
26. Y.J. Chen, C.C. Yuan, K.C. Chow, P.H. Wang, C.R. Lai, M.S. Yen, and L.S. Wang Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients Gynecol. Oncol. 97 1 2005 110 117
27. S.Y. Yoon, J.M. Kim, J.H. Oh, Y.J. Jeon, D.S. Lee, J.H. Kim, J.Y. Choi, B.M. Ahn, S. Kim, H.S. Yoo, Y.S. Kim, and N.S. Kim Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags Int. J. Oncol. 29 2 2006 315 327
28. H.C. Chang, Y.L. Chen, C.P. Chan, K.T. Yeh, S.J. Kuo, C.J. Ko, and H.Y. Fang Overexpression of dihydrodiol dehydrogenase as a prognostic marker in resected gastric cancer patients Dig. Dis. Sci. 54 2 2009 342 347
29. K.C. Chow, M.P. Lu, and M.T. Wu Expression of dihydrodiol dehydrogenase plays important roles in apoptosis- and drug-resistance of A431 squamous cell carcinoma J. Dermatol. Sci. 41 3 2006 205 212
30. D.C. Seo, J.M. Sung, H.J. Cho, H. Yi, K.H. Seo, I.S. Choi, D.K. Kim, J.S. Kim, A.M. A. El-Aty, and H.C. Shin Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells Mol. Cancer 6 2007 75
31. N. Mitsutake, A. Iwao, K. Nagai, H. Namba, A. Ohtsuru, V. Saenko, and S. Yamashita Characterization of side population in thyroid cancer cell lines: cancer stem-like cells are enriched partly but not exclusively Endocrinology 148 4 2007 1797 1803 (Pubitemid 46457095)
32. C.W. Chien, I.C. Ho, and T.C. Lee Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells Carcinogenesis 30 10 2009 1813 1820
33. H.B. Deng, M. Adikari, H.K. Parekh, and H. Simpkins Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase Cancer Chemother. Pharmacol. 54 4 2004 301 307 (Pubitemid 39304424)
34. H.W. Wang, C.P. Lin, J.H. Chiu, K.C. Chow, K.T. Kuo, C.S. Lin, and L.S. Wang Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin Int. J. Cancer 120 9 2007 2019 2027
35. J. Chen, M. Adikari, R. Pallai, H.K. Parekh, and H. Simpkins Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells Cancer Chemother. Pharmacol. 61 6 2008 979 987 (Pubitemid 351423125)
36. M. Ueda, Y.C. Hung, J.T. Chen, S.H. Chiou, H.H. Huang, T.Y. Lin, Y. Terai, and K.C. Chow Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer Gynecol. Oncol. 102 2 2006 173 181 (Pubitemid 44041634)
37. E. Selga, V. Noé, and C.J. Ciudad Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis Biochem. Pharmacol. 75 2 2008 414 426 (Pubitemid 350298467)
38. T.M. Penning, and J.E. Drury Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms Arch. Biochem. Biophys. 464 2 2007 241 250 (Pubitemid 47214569)
39. A.K. MacLeod, M. McMahon, S.M. Plummer, L.G. Higgins, T.M. Penning, K. Igarashi, and J.D. Hayes Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds Carcinogenesis 30 9 2009 1571 1580
40. J.F. Couture, P. Legrand, L. Cantin, V. Luu-The, F. Labrie, and R. Breton Human 20α-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids J. Mol. Biol. 331 3 2003 593 604 (Pubitemid 36937148)
41. U. Dhagat, S. Endo, R. Sumii, A. Hara, and O. El-Kabbani Selectivity determinants of inhibitor binding to human 20α-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid J. Med. Chem. 51 15 2008 4844 4848
42. N. Usami, T. Yamamoto, S. Shintani, S. Ishikura, Y. Higaki, Y. Katagiri, and A. Hara Substrate specificity of human 3(20)α-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines Biol. Pharm. Bull. 25 4 2002 441 445 (Pubitemid 40044660)
43. P. Brozic, J. Cesar, A. Kovac, M. Davies, A.P. Johnson, C.W. Fishwick, T. Lanisnik Rizner, and S. Gobec Derivatives of pyrimidine, phthalimide and anthranilic acid as inhibitors of human hydroxysteroid dehydrogenase AKR1C1 Chem. Biol. Interact. 178 1-3 2009 158 164
44. D.R. Bauman, S.I. Rudnick, L.M. Szewczuk, Y. Jin, S. Gopishetty, and T.M. Penning Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes Mol. Pharmacol. 67 1 2005 60 68 (Pubitemid 40069966)
45. P. Brozic, T. Smuc, S. Gobec, and T.L. Rizner Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1 Mol. Cell. Endocrinol. 259 1-2 2006 30 42 (Pubitemid 44419585)
46. B. Stefane, P. Brozic, M. Vehovc, T.L. Rizner, and S. Gobec New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3 Eur. J. Med. Chem. 44 6 2009 2563 2571
47. P. Brozic, S. Turk, T. Lanisnik Rizner, and S. Gobec Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening Mol. Cell. Endocrinol. 301 1-2 2009 245 250
48. U. Dhagat, V. Carbone, R.P. Chung, T. Matsunaga, S. Endo, A. Hara, and O. El-Kabbani A salicylic acid-based analogue discovered from virtual screening as a potent inhibitor of human 20α-hydroxysteroid dehydrogenase Med. Chem. 3 6 2007 546 550 (Pubitemid 350303069)
49. O. El-Kabbani, and A. Podjarny Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites Cell. Mol. Life Sci. 64 15 2007 1970 1978 (Pubitemid 47094426)
50. O. El-Kabbani, V. Carbone, C. Darmanin, M. Oka, A. Mitschler, A. Podjarny, C. Schulze-Briese, and R.P. Chung Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity J. Med. Chem. 48 17 2005 5536 5542 (Pubitemid 41209251)
51. T. Petrova, H. Steuber, I. Hazemann, A. Cousido-Siah, A. Mitschler, R. Chung, M. Oka, G. Klebe, O. El-Kabbani, A. Joachimiak, and A. Podjarny Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-Fidarestat complex J. Med. Chem. 48 18 2005 5659 5665 (Pubitemid 41298340)
52. O. El-Kabbani, P.J. Scammells, J. Gosling, U. Dhagat, S. Endo, T. Matsunaga, M. Soda, and A. Hara Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20α-hydroxysteroid dehydrogenase (AKR1C1) J. Med. Chem. 52 10 2009 3259 3264
53. P.J. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 28 7 1985 849 857 (Pubitemid 15012490)
54. D. Lednicer Strategies for Organic Drug Synthesis and Design 1998 Wiley-Interscience New York pp. 31-32